What is it about?
This research focuses on synthesizing and understanding the bioactivities of new benzene-imidazole fused-ring molecules and a series of benzimidazole derivatives. The molecules of interest portray potential inhibition properties for both PARP-1 and DHODH enzymes, which could benefit new anti-cancer agents designing. It could also serve as a contributor to drug designing and development by providing a platform for the construction of organic molecules. The synthesis of new molecules utilizing organic reactions could provide a theoretical basis to elaborate biological experimentation. This research mainly targets those cancer patients with BRCA-2 deficiency. Support from cancer society, physicians, funding from ministry and clinicians are needed for the progress of this research.
Photo by Hans Reniers on Unsplash
Why is it important?
Chemotherapy treatment kills both cancerous and healthy cells, and it works throughout the whole body. There is a need for a better alternative with lesser side effects for cancer patients. Therefore, discovery and development of potent, selective and safe drugs are crucial. Benzimidazole derivatives possess good pharmacological and antitumor activity, including PARP and DHODH inhibition. Understanding the mechanisms of PARP-1 and DHODH enzymes in DNA replication and repair mechanisms involved in the hyper-proliferation of cancer cells and targeting the activity of these enzymes for anti-cancer therapy would be beneficial.
Read the Original
This page is a summary of: Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH, Bioorganic & Medicinal Chemistry, August 2015, Elsevier, DOI: 10.1016/j.bmc.2015.05.051.
You can read the full text:
The following have contributed to this page